口服铁剂治疗:提高疗效与改善结局的当前概念与未来前景
缺铁和缺铁性贫血是全球公共健康问题,最常影响儿童、孕妇和育龄女性。口服铁盐补充是常用治疗,但需数倍于推荐膳食摄入量才能有效吸收,过量肠道铁引起胃肠副作用并影响肠道微生物组。本文综述口服铁补充的新研究,聚焦不同铁剂跨越肠上皮的分子转运机制及是否受铁调素调控。
要点
- 缺铁性贫血通常使用铁盐(如FeSO4)口服补充,但需数倍于推荐膳食摄入量才能有效吸收。
- 过量肠道铁引起胃肠副作用,降低依从性,并对肠道微生物组产生负面影响。
- 近期研究旨在寻找吸收更好的新型铁剂,以便使用较低有效剂量。
核心结论
- 本文概述口服铁补充的新兴研究,聚焦不同补充铁形式跨越肠上皮的分子转运机制及是否受铁调素调控。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 缺铁和缺铁性贫血最常影响儿童、孕妇和育龄女性。
- 缺铁性贫血通常使用铁盐(如FeSO4)口服补充,但可能需要数倍于推荐膳食摄入量的剂量才能有效吸收。
- 过量肠道铁引起胃肠副作用,降低依从性,并对肠道微生物组产生负面影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron deficiency (ID) and iron-deficiency anaemia (IDA) are global public health concerns, most commonly afflicting children, pregnant women and women of childbearing age. Pathological outcomes of ID include delayed cognitive development in children, adverse pregnancy outcomes and decreased work capacity in adults. IDA is usually treated by oral iron supplementation, typically using iron salts (e.g. FeSO4 ); however, dosing at several-fold above the RDA may be required due to less efficient absorption. Excess enteral iron causes adverse gastrointestinal side effects, thus reducing compliance, and negatively impacts the gut microbiome. Recent research has sought to identify new iron formulations with better absorption so that lower effective dosing can be utilized. This article outlines emerging research on oral iron supplementation and focuses on molecular mechanisms by which different supplemental forms of iron are transported across the intestinal epithelium and whether these transport pathways are subject to regulation by the iron-regulatory hormone hepcidin.
引用
- Ebea-Ugwuanyi PO, Vidyasagar S, Connor JR, et al. Oral iron therapy: Current concepts and future prospects for improving efficacy and outcomes. Br J Haematol. 2024. PMID: 38253961. doi:10.1111/bjh.19268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。